Hypoxia-inducible factor-1α in vascular smooth muscle regulates blood pressure homeostasis through a peroxisome proliferator-activated receptor-γ-angiotensin II receptor type 1 axis

Hypertension

Volumn 62, Issue 3, 2013, Pages 634-640

  Huang, Yan ^a   Di Lorenzo, Annarita ^b   Jiang, Weidong ^a   Cantalupo, Anna ^b,c   Sessa, William C ^a   Giordano, Frank J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

angiotensins; HIF 1 ; hypertension; muscle, smooth, vascular; PPAR

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TELMISARTAN;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL WALL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EX VIVO STUDY; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL;

ANGIOTENSINS; HIF-1Α; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; PPAR-Γ;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MESENTERIC ARTERIES; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION;

EID: 84883280223     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00160     Document Type: Article

References (36)

1. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation. 2011;123:e18-e209.
2. Sliwa K, Stewart S, Gersh BJ. Hypertension: A global perspective. Circulation. 2011;123:2892-2896.
3. Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med. 2011;13:e11.
4. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749-756.
5. Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens. 1990;8:565-572.
6. Lucius R, Gallinat S, Busche S, Rosenstiel P, Unger T. Beyond blood pressure: New roles for angiotensin II. Cell Mol Life Sci. 1999;56:1008-1019.
7. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
8. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature. 1991;351:230-233.
9. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850-2870.
10. Stegbauer J, Coffman TM. New insights into angiotensin receptor actions: From blood pressure to aging. Curr Opin Nephrol Hypertens. 2011;20:84-88.
11. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem. 1993;268:24543-24546.
12. Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and endorgan protection: Pharmacological rationale and evidence. J Hypertens Suppl. 1998;16:S3-S9.
13. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92:10663-10667.
14. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, Takeshita A. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834-1839.
15. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
16. Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD. Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculaturé J Biol Chem. 2010;285:9311-9316.
17. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004;43:661-666.
18. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 1999;48:1448-1453.
19. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
20. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115:500-508.
21. Lei L, Mason S, Liu D, Huang Y, Marks C, Hickey R, Jovin IS, Pypaert M, Johnson RS, Giordano FJ. Hypoxia inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von hippel-lindau protein. Mol Cell Biol. 2008;11:3790-3803.
22. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009;24:97-106.
23. Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, Tokarska-Schlattner M, Aasum E, Bogdanova A, Perriard E, Perriard JC, Larsen T, Pedrazzini T, Krek W. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 2009;9:512-524.
24. Ray JB, Arab S, Deng Y, Liu P, Penn L, Courtman DW, Ward ME. Oxygen regulation of arterial smooth muscle cell proliferation and survival. Am J Physiol Heart Circ Physiol. 2008;294:H839-H852.
25. Gao W, Ferguson G, Connell P, Walshe T, Murphy R, Birney YA, O'Brien C, Cahill PA. High glucose concentrations alter hypoxia-induced control of vascular smooth muscle cell growth via a HIF-1alpha-dependent pathway. J Mol Cell Cardiol. 2007;42:609-619.
26. Huang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH, Johnson RS, Giordano FJ. Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J. 2004;18:1138-1140.
27. Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J. LRP: Role in vascular wall integrity and protection from atherosclerosis. Science. 2003;300:329-332.
28. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49:341-346.
29. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000;342:626-633.
30. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxiamediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485-490.
31. Semenza GL. HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010;20:51-56.
32. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N, Johnson RS. Loss of HIF-1alpha in endothelial cells disrupts a hypoxiadriven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 2004;6:485-495.
33. Cordell HJ. Epistasis: What it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet. 2002;11:2463-2468.
34. Huang Y, Giordano FJ. Chapter 13. Oxygen as a direct and indirect biological determinant in the vasculature. Methods Enzymol. 2008;444:285-304.
35. Bento CF, Pereira P. Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia. 2011;54:1946-1956.
36. Ketsawatsomkron P, Lorca RA, Keen HL, Weatherford ET, Liu X, Pelham CJ, Grobe JL, Faraci FM, England SK, Sigmund CD. PPARγ regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity. Circ Res. 2012;111:1446-1458.